Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

| More on:
Excited couple celebrating success while looking at smartphone.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Citi has put a buy rating on a biotech giant due to strong immunoglobulin demand, particularly for CIDP treatment.
  • Bell Potter has upgraded an online retailer to a buy rating, anticipating favourable trading updates and market share growth.
  • Morgans has upgraded an energy company to a buy rating, citing strong quarterly performance and strategic partnership benefits.

It has been another busy week for many of Australia's top brokers. This has led to the release of a number of broker notes.

Three broker buy ratings that you might want to know more about are summarised below. Here's why brokers think these ASX shares are in the buy zone right now:

CSL Ltd (ASX: CSL)

According to a note out of Citi, its analysts have retained their buy rating and $265.00 price target on this biotechnology giant's shares. The broker has been looking into immunoglobulin demand and highlights that it remains strong. It has surveyed neurologists in the United States and found that they are continuing to use it to treat autoimmune neurological disorder CIDP. Given how this makes up almost a quarter of its immunoglobulin sales, Citi thinks this is good news. As a result, it continues to see value in its shares at current levels and is recommending them to clients. The CSL share price is trading at $214.33 this afternoon.

Temple & Webster Group Ltd (ASX: TPW)

A note out of Bell Potter reveals that its analysts have upgraded this online furniture and homewares retailer's shares to a buy rating with a $28.00 price target. The broker is feeling confident ahead of the release of a trading update from Temple & Webster next month. It is expecting the company to benefit from softer comps in the months of September and October and be tracking close to consensus estimates for the first half. Outside this, the broker continues to see catalysts of outperformance as market share capture in an expanded total addressable market is expedited with range, pricing/scale advantages, backed by a strong balance sheet. And with its shares pulling back meaningfully in recent weeks, it thinks now is the time to invest. The Temple & Webster share price is fetching $25.12 at the time of writing.

Woodside Energy Group Ltd (ASX: WDS)

Analysts at Morgans have upgraded this energy giant's shares to a buy rating with a $30.50 price target. According to the note, the broker was pleased with the company's performance in the third quarter, noting that it was a strong operational and sales result. Another positive is the entry of US midstream player Williams into the Louisiana joint venture. Morgans believes that Willams will help de-risk infrastructure and feed gas delivery. Combined with good macro news, the broker isn't surprised that Woodside shares are gaining support with investors. The Woodside share price is trading at $24.30 on Friday.

Citigroup is an advertising partner of Motley Fool Money. Motley Fool contributor James Mickleboro has positions in CSL, Temple & Webster Group, and Woodside Energy Group. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Temple & Webster Group. The Motley Fool Australia has recommended CSL and Temple & Webster Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

A male sharemarket analyst sits at his desk looking intently at his laptop with two other monitors next to him showing stock price movements
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »

A wad of $100 bills of Australian currency lies stashed in a bird's nest.
Broker Notes

Up 40% in a year, why Macquarie expects this ASX 200 dividend stock to keep outperforming in 2026

Macquarie forecasts more outperformance from this fast-rising ASX 200 dividend stock.

Read more »

A man wearing glasses and a white t-shirt pumps his fists in the air looking excited and happy about the rising OBX share price
Broker Notes

These ASX 200 shares could rise 30% to 40%

Looking for big returns? Bell Potter thinks these shares could be the ones to buy.

Read more »

Man standing on the roof rack of a van next to boxes and gear
Broker Notes

Broker tips 30% upside for this ASX 200 stock

This ASX 200 stock could now be a buy-low option.

Read more »

Broker looking at the share price.
Broker Notes

Broker ratings on 6 ASX shares about to join the ASX 200

These 6 companies will enter the ASX 200 in the December quarter rebalance. Should you buy them?

Read more »

A happy elderly woman smiles and cheers as she looks at good investment news on her laptop.
Broker Notes

Macquarie forecasts this $3.4 billon ASX healthcare share is set surge 33%

Macquarie tips material outperformance from this ASX healthcare share in 2026.

Read more »

Man looking at digital holograms of graphs, charts, and data.
Broker Notes

3 reasons this ASX 300 tech stock is forecast to leap 83% in 2026

A leading broker expects some outsized returns from this ASX 300 tech share. Let’s see why.

Read more »

gold share price represented by speeding golden bullet
Broker Notes

Why this surging ASX All Ords gold stock is tipped to rocket another 233%

A leading broker expects outsized gains from this ASX All Ords gold stock. But not without risk.

Read more »